The new facility will further strengthen WuXi AppTec’s global pharmaceutical development and manufacturing platform, enabling drug developers to accelerate projects from the preclinical to commercial stage
STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.
According to WuXi STA, the company has already established an industry leading process development platform with more than 1000 scientists and five sites located in China and the US. The company’s Jinshan site currently focuses on manufacturing APIs and advanced intermediates from the kilo to metric ton scale. The site has been approved by multiple international regulatory agencies, including the US FDA.
The new R&D centre will be located next to the existing Jinshan drug substance manufacturing site, adding more than 30,000 m2 of laboratory space and 500 scientists.
Upon completion, the expanded Jinshan campus will be able to offer an integrated one-site solution for partners to push forward innovative APIs and advanced intermediates – from preclinical and clinical development through to global commercial launch. The new campus will also provide access to industry leading technology platforms such as flow chemistry, biocatalysis and high potency from the laboratory to a commercial scale.
Shanghai Jinshan District has enjoyed sustained economic growth in recent years, via its strategic focus on smart manufacturing and has attracted many biotechnology and pharmaceutical companies including WuXi STA.
“This new R&D centre in Caojing Town, Jinshan is a result of the long -term win-win collaboration between the Jinshan government and WuXi STA. The project will further strengthen the life science industry ecosystem in Jinshan District,” said Quanquan Zhang, vice governor of Jinshan.
“The new R&D centre is a reflection of our commitment to better serve customers worldwide and support growth in the local economy, as well as the biopharmaceutical ecosystem in Jinshan,” said Dr Minzhang Chen, CEO of WuXi STA.
“As we continuously strengthen the capability and capacity of our platform, we will enable more global partners to shorten development timelines and lower the cost of new drug development, improving the lives of people around the world.”